<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04011475</url>
  </required_header>
  <id_info>
    <org_study_id>1237-0086</org_study_id>
    <nct_id>NCT04011475</nct_id>
  </id_info>
  <brief_title>A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment</brief_title>
  <official_title>Taiwan Outcomes and Real-world Treatment Options for Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to collect the data on Chronic Obstructive Pulmonary Disease (COPD) patients who were
      administered with Long-Acting Beta-Agonist/ Long-Acting Muscarinic Antagonist (LABA/LAMA)
      (Fixed-dose Combination (FDC) or free combo) or LAMA treatment
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 29, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to the first moderate or severe COPD exacerbation</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of mild/moderate/severe exacerbation</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to (e.g., severe airflow limitation, diagnosis of asthma, worsening exacerbation) from LABA/LAMA escalating to LABA/LAMA/ICS or from LAMA to dual therapy</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of reasons (e.g., severe airflow limitation, diagnosis of asthma, worsening exacerbation) from LABA/LAMA escalating to LABA/LAMA/ICS or from LAMA to dual therapy</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients receiving LABA/LAMA switched to triple therapy or LAMA switched to dual therapy</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pulmonary function after LABA/LAMA or LAMA initiation will be evaluated by COPD Assessment Test (CAT)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with use of rescue medications</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pulmonary function after LABA/LAMA or LAMA initiation will be evaluated bymodified Medical Research Council dyspnea scale (mMRC)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>mMRC is a 4-item questionnaire for measuring the severity of dyspnea of patients. If mMRC scale of the patient is &gt; 2, it means the patient may suffer from dyspnea.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1800</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Subjects with Tiotropium and Olodaterol</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects treated with other LABA/LAMA therapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects treated with LAMA therapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium + Olodaterol</intervention_name>
    <description>Spiolto®</description>
    <arm_group_label>Subjects with Tiotropium and Olodaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Other LABA/LAMA</intervention_name>
    <description>tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium</description>
    <arm_group_label>Subjects treated with other LABA/LAMA therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAMA</intervention_name>
    <description>aclidinium bromide, glycopyrronium, tiotropium, umeclidinium</description>
    <arm_group_label>Subjects treated with LAMA therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The data will be retrospectively abstracted from the medical chart after eligibility
        assessment. Eligible patients will be categorized into the cohort A (patients treated with
        Tio + Olo), B (patients treated with other LABA/LAMA therapy), and C (patients treated with
        LAMA therapy).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who fulfil ALL the following criteria are included.

          1. Patients who diagnosed with COPD who were prescribed with LABA/LABA (FDC or free
             combo) as a new initiation or switching from other therapy (i.e., single/dual/triple),
             or newly receiving LAMA treatment for 3 months at least prior to 30 June 2018

          2. Male or female patients ≥ 40 years of age

        Exclusion Criteria:

        1. Patients who meet the following criterion are not included.

          -  Patients with documented diagnosis of bronchial asthma, asthma-COPD overlap syndrome
             (ACOS), bronchiectasis, cystic fibrosis, or lung cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ditmanson Medical Foundation Chia - Yi Christian Hospital</name>
      <address>
        <city>Chia YI City</city>
        <zip>600</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CGMH Chia YI</name>
      <address>
        <city>Chia YI City</city>
        <zip>613</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eda hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>824</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CGMH Kaohsiung</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Far east memorial hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China medicine memorial hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VGH Taichung</name>
      <address>
        <city>Taichung City</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makay memorial hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheng Hsin general hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Tzu Chi hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>231</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CGMH Linkou</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://trials.boehringer‐ingelheim.com/trial_results/ clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.
Also, Researchers can use the following link http://trials.boehringeringelheim.com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

